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Abstract
This study presents the risk of various cancers in relation
to ginseng intake based on the data from a case-control
study conducted in the Korea Cancer Center Hospital.
Ginseng intakers had a decreased risk [odds ratio 0.50,
95% confidence interval (CI) 0.44-0.58] for cancer
compared with nonintakers. On the type of ginseng, the
odds ratios for cancer were 0.37 (95% CI 0.29-0.46)
for fresh ginseng extract intakers, 0.57 (95% CI 0.48-
0.68) for white ginseng extract intakers, 0.30 (95% CI =
0.22-0.41) for white ginseng powder intakers, and 0.20
(95% CI = 0.08-0.50) for red ginseng intakers. Intakers
of fresh ginseng slice, fresh ginseng juice, and white
ginseng tea, however, showed no decreasing risk. There
was a decrease in risk with the rising frequency and
duration of ginseng intake, showing a dose-response
relationship. On the site of cancer, the odds ratios were
0.47 for cancer of the lip, oral cavity, and pharynx; 0.20
for esophageal cancer; 0.36 for stomach cancer; 0.42 for
coborectal cancer; 0.48 for liver cancer; 0.22 for
pancreatic cancer; 0.18 for laryngeal cancer; 0.55 for
lung cancer; and 0.15 for ovarian cancer. In cancers of
the female breast, uterine cervix, urinary bladder, and
thyroid gland, however, there was no association with
ginseng intake. In cancers of the lung, lip, oral cavity and
pharynx, and liver, smokers with ginseng intake showed
decreased odds ratios compared with smokers without
ginseng intake. These findings support the view that
ginseng intakers had a decreased risk for most cancers
compared with nonintakers. In conclusion, further studies
will be necessary to elucidate what type of compounds
caused this effect. To elucidate the mechanisms involved,
extensive chemical, biochemical, molecular biological,
immunological, and intervention studies must be
conducted.
Introduction
The ginseng root has been used empirically for thousands of
years in Asian countries. Since 1965, several pharmacological
activities have been reported for ginseng extracts or ginseng
dammarane saponins, including effects on the central nervous
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system; antipsychotic action; tranquilizing effects; protection
from stress ulcers; increase of gastrointestinal motility; antifa-
tigue action; endocninobogical effects; enhancement of sexual
behavior; acceleration of metabolism; on synthesis of cambohy-
drates, lipids, RNA, and proteins (1-5).
The species of ginseng are Panax ginseng C. A. Meyer
(Korean ginseng), which is cultivated in Korea, Japan, China
and Russia; Panax quinquefolius L. (American ginseng), which
is raised in the eastern United States and Canada; Panax ja-
ponicus C. A. Meyer (Japanese ginseng), which is also called
Bamboo ginseng; and Panax notoginseng (Bunk) F.H. Chen
(Sanchi-ginseng), a native of southwest China (Yunnan and
Kwangsi Provinces). In Korea, Panax ginseng C. A. Meyer is
collected after 2 to 6 years of cultivation, and it is classified into
three types depending on how it is processed: (a) fresh ginseng
(less than 4 years old and can be consumed in the fresh state);
(b) white gnseng (4-6 years old and then dried after peeling);
and (c) med ginseng, which is harvested when 6 years old and
then steamed and dried (Fig. 1). Each type of ginseng was
categorized further into several forms of ginseng products:
fresh sliced; juice; extract (tincture or boiled extract); powder;
tea; tablet; capsule; and other forms.
We hypothesized that the life-prolonging effect of ginseng
described by Shennong (6) during the Liang Dynasty in China
may be due to the preventive activity of ginseng against the
development of cancers. We therefore carried out extensive
animal experiments in 1978 to investigate whether ginseng
inhibited cancinogenesis. We demonstrated that the ned ginseng
extract has anticancinogenic effects against pulmonary tumors
induced by various chemical carcinogens including 9,10-dim-
ethyl-1,2-benzanthmacene, urethane, aflatoxin B1, and N-2-
fluomenylacetamide in a long-term carcinogenesis model using
mice (7, 8). This anticarcinogenic mechanism was partly in-
volved in the elevation of the natural killer cell activity (9). The
medium term (9 weeks) model system also revealed the anti-
cancinogenicity of ginseng on pulmonary adenomas induced by
benzo(a)pyrene in newborn mice (10-12). We further investi-
gated whether fresh ginseng or white ginseng has similar anti-
carcinogenic effects, and also if their anticarcinogenic effects
are related to types and ages of ginseng using benzo(a)pymene.
A significant anticarcinogenic effect was observed in 6-year-
old dried powder on extracted fresh ginseng; 5- and 6-year-old
white ginseng powder on extract; and 4-, 5-, and 6-year-old red
ginseng powder on extract (13, 14).
It has recently been shown that the biomass of ginseng
tincture protected Ehnich ascitic tumor cells against the muta-
genie action of urea nitmosomethyl in vitro and in s’is’o (15).
Sanchi ginseng inhibited the early antigen activation of Epstein-
Barn virus in Raji cells induced by TPA and n-butylic acid,
pulmonary tumonigenesis induced in mice by 4-nitroquinoline-
N-oxide and glycerol (16, 17), and ginseng inhibited the liver
cancer induced by diethylnitrosamine in rats (18). It has also
been reported more recently that tissue culture biomass tinctureFig. /. Panax ginseng C. A. Meyer in Korea are classified into fresh ginseng (fr/i). less than 4 years old and can be consumed in the fresh state: white ginseng (right),
4-6 years old and then dried after peeling: and red ginseng (center), harvested when 6 years old and then steamed and dried.
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obtained from culture cells of Panax ginseng C. A. Meyer had
a marked inhibitory effect on mammary tumors, mostly ade-
nocarcinoma, induced by N-methyl-N-nitrosoumea administra-
tion in mats (19).
We have previously reported the results on the effect of
ginseng intake in a case-control study conducted on patients
admitted to Korea Cancer Center Hospital (20). There was a
decrease in cancer risks for ginseng intakers.
In order to explore further (a) the types of ginseng prod-
ucts that have the most prominent cancer preventive effect,
(b) the reproducibility of the dose-response relationship, (c) the
duration of ginseng consumption that has a significant preven-
tive effect, (d) the types of cancer which can be prevented by
ginseng, and (e) the effect of ginseng on cancers associated
with smoking, we extended the number of subjects for a case-
control study on 1987 pairs.
Patients and Methods
The sites studied which are classified according to the 9th
Revision of the International Classification of Diseases for
Oncology, WHO (21), were as follows; cancers of the lip, oral
cavity and pharynx, esophagus, stomach, cobonectum, liven,
pancreas, larynx, lung, female breast, uterine cervix, ovary,
urinary bladder, thyroid gland, and others. All the cases were
confirmed by cytological and/or histopathological examination
as primary cases admitted between February 1987 and Decem-
ber 1990 at the Korea Cancer Center Hospital, which special-
izes in cancer control and functions as a general hospital for the
neighborhood.
The controls were selected from a pool of patients diag-
nosed as having noncancerous diseases at the hospital. Each
case was matched with I control based on the year of birth
(within 2 years), sex, and the admission date (within 3 months).
When there were too many candidates for controls, the patient
who was admitted on the nearest date was selected. The disease
sites in male control patients were the stomach (495), thyroid
(120), colon (81), kidney (93), oral cavity (85), lung (51), and
others (95); for females, they were the uterus (351), breast
( 177), thyroid ( 170), ovary (75), stomach (46), liver (25), colon
(16), and others (55). The types of diseases of controls were
mainly acute diseases, that is, acute or unspecified gastnitis in
the stomach, goiter in the thyroid gland, acute appendicitis and
obsruction in the colon, acute pyelonephnitis and stone in the
kidneys, tonsilitis and laryngophanyngitis in the oral cavity, or
pneumonia and pleurisy in the lungs.
Cases and controls were selected among patients who were
admitted to the hospital as new patients at the beginning of the
study and were interviewed personally in the hospital by three
trained interviewers. Almost every respondent was willing to
answer the questionnaire. Those who had difficulty in answer-
ing because of serious illness were excluded from the study. Of
the eligible cases and controls, 2.2% refused to answer from the
outset on in the course of answering. To obviate biases caused
by the interviewers, the category of the study subjects, i.e. , case
on control, was not known to the interviewers (22). Each study
subject was interviewed according to a standard questionnaire.
All questionnaires were checked for consistency and verified
for accuracy of coding. When information in questionnaires
was incomplete or inconsistent, they were sent back for con-
mection. The questionnaire included information on sociodemo-
graphic characteristics, life-long occupational history, and
smoking and drinking habits. To obtain detailed information
about ginseng intake, we asked subjects to specify their age at
initial intake, their frequency and duration of intake, and the
kind of ginseng. In the case of fresh ginseng, the categories
include fresh slice (thinly sliced pieces taken with or without
honey), fresh extract (ginseng soup boiled for more than 3 h),
on boiled young fresh ginseng moot with chicken. For white
ginseng, the categories include powder (white ginseng in pow-
den form), extract (boiled white ginseng soup), and tea. Red
ginseng was classified into extract (boiled red ginseng soup)
and powder. In addition, multiple combinations among fresh,
white, and red ginseng were included. Interviews on ginseng
intake were carried out by asking the following questions in
order to exactly characterize life-long ginseng intake: (a) have
you even consumed ginseng; (b) at what age did you take
ginseng for the first time; (c) what type of ginseng products
have you taken; and (d) how often (frequency) and how long
(duration) have you used it?. The frequency of ginseng intake
was divided into four categories: (a) no intake; (b) 1-3 times/Cancer Epidemiology, Biomarkers & Prevention 403
3 The abbreviations used are: OR. odds ratio; CI, confidence interval.
Table I Percentage distribution of demographic variables in cancer patients
and controls
Variables Cases
(%)
Male
Controls
(%)
Cases
(%)
Female
Controls
(%)
Total Number 1072 1072 915 915
Age (year)
0-49 32.1 33.8 44.1 52.6
50-59 38.0 42.8 37.4 33.7
60+ 29.9 23.4 18.5 13.7
Mean age 53.5 52.6 49.8 48.4
Marital status
Married 94.8 94.9 78.6 82.9
Widowed 2.6 3.1 18.2 14.0
Other 2.6 2.0 3.2 3.1
Education (year)
None 12.8 1 1.4 25.6 20.9
()-() 38.9 39.8 41.3 41.7
7-12 38.2 37.3 30.3 34.4
13+ tO.i 11.5 2.8 3.0
Religion
None 54.4 52.9 34.4 32.4
Buddhist 23.1 25.3 33.1 34.2
Protestant 1 i .2 14.8 20.8 20.2
Catholic 6.5 4.i 9.2 9.6
Other 4.8 2.9 2.5 3.8
Occupation
Professional and clerical 14.5 17.1 2.4 2.8
workers
Service workers 5.9 10.4 3.8 5.6
Sales workers 10.0 12.1 8.3 9.2
Agricultural workers 36.9 28.8 21.5 16.0
Production workers and 16.3 18.4 5.6 7.7
laborers
No occupation 16.4 13.2 58.4 58.7
year; (c) 4-1 1 times/year; and (d) more than once a month (12
times/year on more).
To evaluate the accuracy of the answers to the question-
name, 10% of both cases and controls were selected and rein-
terviewed 1 year after the first interview. ic is a measure of
agreement with desirable properties. Landis and Koch (23)
have characterized different manges of values for K with respect
to the degree of agreement: K values less than 0.40, poor
agreement beyond chance; 0.40-0.70, fare to good agreement
beyond chance; and greater than 0.75, excellent agreement
beyond chance. The K value for this study was 0.78 (P < 0.01),
which indicated excellent agreement of answers.
Contingency tables were constructed for cases and con-
tmols by demographic and social characteristics, and the ￿ test
was used for significance. The ORs3 and 95% CIs were com-
puted for ginseng intake. These estimates were obtained by
multiple logistic regression to control confounding factors such
as age, sex, education, marital status, smoking, and alcohol
consumption (24-25).
Results
The distribution of total studied cancers and their controls
according to demographic and social characteristics is shown in
Table 2 Odds ratios for cancers and 95% CI according to the
type of ginseng”
.
Type of ginseng
Cancer
.
patients
Controls
(%) OR
95%
CI
No intake of ginseng 921 61)5 l.0() Reference
Intake of ginseng 1066 (53.6) 1382 (69.6) 0.50 0.44-0.58
Fresh ginseng
Fresh slice 210 172 0.79 0.63-1.01
Juice 69 63 0.71 0.49-1.03
Extract 146 255 0.37 0.29-0.46
Extract and powder 25 38 0.40 0.24-0.66
Extract and fresh slice 8 16 0.32 0.i4-0.73
White ginseng
Extract 373 442 0.57 0.48-0.68
Extract and fresh slice 68 79 0.55 0.39-0.77
Extract and powder 15 41 0.22 0.12-0.38
Powder 60 129 0.30 0.22-0.41
Powder and fresh slice 21 31 0.39 0.22-0.67
Tea 43 41 0.69 0.45-1.07
Red ginseng
Extract 6 17 0.20 0.08-0.50
Other 22 58 0.16 0.10-0.25
“ Adjusted for age, sex, marital status, education, smoking, and alcohol
consumption.
Table 1. Among 1987 cases, 1072 (54.0%) were males and 915
(46.0%) were females. The average ages at diagnosis for the
case groups of males and females were 53.5 and 49.8 years,
respectively. There were no significant differences in age, mar-
ital status, educational level, religion, and occupation by sex
between cases and controls. Female cases had fewer years of
schooling and were more often widowed than male cases.
The ORs for cancers according to ginseng intake are
shown in Table 2. Control groups (69.6%) had more ginseng
intake compared with that of cancer patients (53.6%). The OR
for ginseng intakers was 0.50 (95% CI = 0.44-0.58) compared
with nonintakens. According to the type of ginseng product, the
ORs were 0.37 (95% CI = 0.29-0.46) for fresh ginseng extract
intakems, 0.57 (95% CI = 0.48-0.68) for white ginseng
extract intakers, 0.30 (95% CI = 0.22-0.41) for white gin-
seng powder intakers, and 0.20 (95% CI = 0.08-0.50) for
red ginseng intakers. However, intakers of fresh ginseng
slice, fresh ginseng juice, and white ginseng tea showed no
decreasing risks.
Table 3 shows the ORs for frequency and lifetime con-
sumption of ginseng. There was a decrease in risk with rising
frequency of ginseng intake. The OR ranged from 0.60 for
intakers of 1-3 times/year to 0.36 for intakers of more than 1
time/month. To see the cumulative effect of ginseng intake,
total lifetime frequencies of ginseng intake were calculated.
The ORs were reduced gradually as the total frequency of
ginseng intake increased.
For the duration of ginseng intake, the ORs for 1, 2, 3, 4,
and 5 years were 0.64, 0.53, 0.36, 0.45, and 0.31, respectively,
showing a decreasing trend (Table 4). The ORs in those who
had consumed ginseng for 1-5, 6-10, and 1 1-20 years were
0.51, 0.44, and 0.43, respectively, showing a gradual decrease
in the ORs up to 20 years.
The effect of ginseng intake on the organ or site-specific
risks for cancers was studied in the subjects with previous
ginseng intake (Table 5). The ORs were 0.47 for cancer of the
lip, oral cavity, and pharynx; 0.20 for esophageal cancer; 0.3640-’
Tahl e 3 Odds ratios fo r cancers acco rding to fr equency and lifetime consumption o f ginseng
Frequency of ￿
ginseng intake Cases Controls OR” 95% Cl
Male Female
Cases Controls OR” 95% CI Cases Controls OR5 95% CI
Frequency of ginseng intake
None 921 6()5 l.0() Reference 409 234 1.00 Reference 512 371 lOt) Reference
1-3 times/year 417 44(1 0.60 0.5I-().7l 246 231 0.62 0.49-0.79 171 209 0.60 0.47-0.76
4-I I times/year 324 394 0.5i (1.43-0.61 197 223 0.48 0.37-0.62 127 171 0.54 0.42-0.71
I time/month or more 325 548 0.36 0.30-().43 220 384 0.31 0.25-41.39 105 164 0.47 0.39-0.62
Total lifetime consumption of ginseng
None 921 605 1.1)0 Reference 409 452 1.00 Reference 512 371 1.00 Reference
1-5(1 774 903 0.55 0.47-4)63 452 501 0.51 t).42-0.63 322 402 0.58 0.48-0.71
51-101) 1(13 139 0.46 0.35-4)61 75 100 0.41 0.29-0.58 28 39 0.56 0.34-0.93
101-300 109 185 0.34 0.27-4)45 8t) 131 0.32 (1.23-0.44 29 54 0.39 0.25-4)61
301-500 28 50 0.31 t).l9-4).49 20 29 0.33 0.18-0.62 8 21 0.29 0.14-4)63
501 + 52 105 0.28 0.20-0.39 36 77 0.25 0.16-4)38 16 28 0.42 0.23-0.79
“ Adjusted for age. sex, marital status, education. smoking, and alcohol consumption.
I’ Adjusted for age, marital status. education. smoking, and alcohol consumption.
Table 4 Odds ratios fo r cancers ac cording to duration of gins eng intake”
Duration of
ginseng intake Cases Controls OR 95% CI
(yr)
None 92 I 64)5 1.00 Reference
I 361 362 0.64 0.54-0.77
2 162 197 t).53 0.42-4)66
3 I 16 21)1 0.36 t).28-0.47
4 82 1 14 0.45 0.33-0.61
5 57 1 18 t).3l 0.22-1)44
x2 linear trend test 103.74 P < 0.(X)l
￿2 homogeneity test
i- = 1 1 1.1)8 P < 0.(X)l
I-S 778 992 1)51 0.44-0.59
6-10 157 214 t).44 0.35-0.56
I 1-20
x2 linear trend test
81 1 17 0.43 0.33-41.59
￿- = 77.32 P < 0.901
x2 homogeneity test = 106.59 P < 0.18)1
.‘ Adjusted for age.
consumption.
sex, marital status, education, smoking. and alcohol
Table 5 Odds rat ios for various ca ncers according to ginsen g intakers
Cases Controls
Site of cancer Never taken/
ever taken
Never taken/
ever taken
OR 95% CI
Lip, oral cavity, 67/92 40/1 19 4)47 0.29-4)76
and pharynx
Esophagus 40/47 14/73 0.2t) 0.09-0.38
Stomach 142/158 76/224 0.36 0.25-0.52
Colon and rectum 55/63 32/86 0.42 0.24-0.74
Liver 108/156 67/197 0.48 0.33-0.70
Pancreas 12/i I 5/18 0.22 0.05-0.95
Larynx 21/19 8/32 0.18 0.06-0.54
Lung 120/156 81/195 0.55 0.38-0.79
Female breast 82/92 70/109 0.63 0.4(1-1.05
Cervix uteri 156/146 132/170 0.72 0.52-1.01
Ovary 17/5 8/14 0.15 0.04-0.60
Urinary bladder 23/40 16/47 0.64 0.28-1.47
Thyroid gland 16/24 14/26 0.96 0.38-2.44
Others 53/61 35/79 0.48 0.27-0.85
Adjusted for age. sex. marital status, education, smoking. and alcohol
consumption.
for stomach cancer; 0.42 for colon and rectal cancer; 0.48 for
liven cancer; 0.22 for pancreatic cancer; 0.18 for laryngeal
cancer; 0.55 for lung cancer; and 0. 15 for ovarian cancer. In
cancers of the female breast, uterine cervix, urinary bladder,
and thyroid gland, however, there was no association with
ginseng intake.
Table 6 shows the effect of ginseng on the risk of cancer
associated with smoking. Smokers without ginseng intake for
cancers of the lung, lip, oral cavity, pharynx, and liver showed
significantly increasing risks. However, the ORs for smokers
who had consumed ginseng decreased, showing 1.99 for lung
cancer; 2.36 for cancer of the lip, oral cavity, and pharynx; and
2.09 for liver cancer compared with nonsmokers who had
consumed ginseng. There was no association with ginseng
intake in cancers of the esophagus, stomach, and colomectum.
Discussion
In our previous case-control study conducted on 905 pairs of
inpatients at Korea Cancer Center Hospital, we had observed
that cancer risk decreased in ginseng intakens (20). In the
present study we extended the number ofsubjects to 1987 pains,
including the above-mentioned pairs, and studied: (a) the types
of the most prominent cancer-preventive ginseng products;
(b) the reproducibility of the dose-response relationship; (c) the
significant preventive duration of ginseng consumption;
(d) types of cancer which can be prevented by ginseng; and
(e) the effect of ginseng on cancers associated with smoking.
The proportion of ginseng intakens to controls of this study,
69.6%, was similar to the 71.6% average ofothen sources from
four major ginseng cultivation areas (Kangwha-eup, 70.7%;
Keumsan-eup, 85.4%; Muju-eup, 89.4%; Punggi-eup, 81.8%)
and in a comparison area (Keumchon-eup, 61.4%) for perform-
ing a prospective study in August 1988. The OR for cancer in
relation to ginseng intake, 0.50, was similar to the previous data
(0.56).
Ginseng is believed to have been used for about 2000
years in Oriental countries. Even some highly educated or high
income people who preferred Western medicine to Korean
traditional medicine took mainly white ginseng extract or pow-
den that could be preserved as a tonic. In the past it was rather
expensive, and only a few high level people could afford it. As
the socioeconomic status of Korea began to improve about 15
or 20 years ago, and Koreans began to prefer Korean traditional
teas, and the effect of ginseng became widely known, a lot of6 year (140 g)
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Ta/ole 6 Odds ratios for cancers according to ginseng intake and smoking”
Cancers Ginseng intake
OR
Nonsmokers
95% CI
Smokers
￿ ￿ ￿ ￿
OR 95￿ (‘I
Lung Ever taken
Never taken
1.90(27)”
2.1 1 (40)
Reference
1.08-4.15
1.99(81)
4.13 (128)
1.25-3.19
1.90-9.03
l.ip. oral cavity. and pharynx Ever taken
Never taken
1.48) (23)
2.13 (24)
Reference
0.95-4.79
2.36 (43)
4.41 (6￿))
1.23-4.51
1.29-15.04
Esophagus Ever taken
Never taken
1(8) (5)
t).51 (5)
Reference
0.10-2.69
0.13 (35)
0.38 (42)
0.06-4)31
(1.09-1.62
Stomach Ever taken
Never taken
I .181 (56)
2.73(81))
Reference
1.61-4.64
2.90 (62)
1.90(101)
I.79-4.7(1
0.84-￿l.28
Colorectum Ever taken
Never taken
1.04) (3!)
2.1 1 (35)
Reference
1.03-4.34
3.25 (20)
2.45 (31)
1.25-8.44
0.6(1-1)1.13
l.iver Ever taken
Never taken
1.00 (31)
I .68 (27)
Reference
0.79-3.57
2.09 (81)
2.50 ( I 25)
1.33-3.29
1.06-5.92
“ Adjusted for age. sex. education. and alcohol consumption.
/. Numbers in parentheses. number of cancer patients.
Fig. 2. Fresh state of Panax ginseng C. A. Meyer at 1.5. 3, 4, 5. and 6 years.
people began to drink ginseng tea. Ginseng tea is served as
much as coffee. At home some take white ginseng powder with
honey by the spoon. Since electric appliances have become
widely available, others purchase the 4-year-old fresh ginseng
roots from the ginseng market, boil them with dates and ginger
for about 3 h as white ginseng, store its brownish soup in the
refrigerator. and drink it every day. Some people often buy red
ginseng extract powder or ginseng tincture from department
stores or ginseng distribution centers and drink it in hot water
with sugar like instant coffee. Some take sliced fresh ginseng on
ginsengjuice at home or at Insam Chajip (ginseng drink corners
in Korean).
The preventive effect of ginseng against cancers was ob-
served in almost all types of ginseng product, which include
fresh ginseng extract, white ginseng extract, white ginseng
powder, and red ginseng products but exclude fresh ginseng
slice, fresh ginsengjuice, and white ginseng tea. The absence of
a preventive effect with fresh ginseng slice and fresh ginseng
juice intake is consistent with our previous data (20); this again
was supported by the results of animal studies on a medium
term benzo(a)pymene anticancinogenicity bioassay system with
the use of4-yeam-old fresh ginseng root (10) and 1.5- to 5-year-
old dried fresh ginseng (13, 14; Fig. 2). The number of subjects
who consumed expensive med ginseng was too small to evaluate
any beneficial effect in the earlier study, but in this study the
OR of med ginseng products intakers was the lowest at 0.20.
To examine the reproducibility of dose-response relation-
ships between ginseng consumption and cancer, all types and
forms of ginseng products were combined, and the frequency of
ginseng intake was categorized into four levels as in the earlier
study. The ORs for decreasing levels of ginseng intake were
similar to those in the earlier study in males and females, and
a trend test showed a significant decrease in the proportion of
cancer cases, with an increasing frequency of intake for both
males and females, respectively. To confirm the cumulative
effect of ginseng intake, total lifetime frequencies of ginseng
intake were calculated, and the ORs were reduced gradually as
the total frequency of ginseng intake increased as in the earlier
study. The OR began to decrease after I year of ginseng intake
and progressively declined until after 5 years of intake. The406
ORs in those who consumed ginseng for 6-10 and 11-12 years
gradually decreased further. We also analyzed the effect of age
of first ginseng intake on risk for cancers. There was no sig-
nificant difference in the OR between those who began to use
ginseng between the ages of 30-39 and after age 60. In both
groups the preventive effect appeared 1 year after the first
ginseng intake and increased with the duration of consumption
(data not shown).
According to the site of cancer, ginseng intake decreased
the OR for cancers of the lip, oral cavity, phanynx, esophagus,
stomach, coborectum, liver, pancreas, larynx, lung, and ovary.
However, there were inconsistent and weak associations be-
tween ginseng intake and cancers of the female breast, uterine
cervix, urinary bladder and thyroid gland. The ORs for cancers
of the breast and uterine cervix showed 0.63 (95% CI
0.40-1.05) and 0.72 (95% CI 0.52-1.01), respectively. Con-
sidening that biomass tincture obtained from culture cells of
Panax ginseng C. A. Meyer showed a marked inhibitory effect
on mammary adenocarcinoma in rats induced by N-methyl-N-
nitrosourea (19), and also that the upper limits of the 95%
confidence interval of cancers of the breast and uterine cervix
were close to 1.00, we expect an inhibitory effect in these
cancers. The total number of other cancers shown in Table 5,
1 14 cases, included cancers of the kidney (22), bile duct (21),
nasal cavity (20), and malignant lymphoma (20). The rest were
cancers of the corpus uteri, prostate gland, vagina, bone, testis,
penis, abdomen, duodenum, pleura, and placenta. The OR for
all other cancers was 0.48 (95% CI = 0.27-0.85). Therefore, it
suggests that most cancers could be prevented by intake of
ginseng.
It is well recognized that /3-carotene, retinol, 13-cis-neti-
noic acid, vitamin C, vitamin E, and isotmetinoin act as inhib-
itors of lung and skin cancers; 4-OH phenyl-retinamide (phen-
metinide) and tamoxifen of breast cancer; folic acid and trans-
retinoic acid of cervix cancer; and ￿-camotene, fiber, calcium
vitamin C, vitamin E, and pinoxicam of colon cancer (26-29).
However, ginseng prevented almost all types of cancer irre-
spective of the pathological types in our study. It is very hard
to understand how the intake of ginseng could prevent the
development of nearly all cancers. Ginseng might be effective
in the primary prevention of cancers and have an effect in the
early initiation stage of carcinogenesis. Considering the reports
on the higher incidence of lung cancer among men who me-
ceived /3-carotene (30); on the back of anticancer effects of anti-
oxidant vitamins including vitamin C, vitamin E, and /3-carotene
(3 1); and on high grade endometrial carcinoma in patients and
hepatocarcinogenic activity in rats treated with tamoxifen (which
was expected to prevent breast cancer; Refs. 32 and 33), interest
should be taken in the cancer-preventive effects of ginseng.
It is well known that the incidence of lung cancer is high
in smokers (34, 35), and it has also been reported that smoking
enhanced the risk of cancers of the oral cavity (35, 36), phamynx
(35, 37), esophagus (35, 38), stomach (39), and liven (40, 41).
In the present study, the risk of cancers of the lung, lip, oral
cavity, pharynx, and liver associated with smoking was reduced
with ginseng intake. Smokers with ginseng intake for these
cancers showed significantly increasing risks, but the ORs
decreased compared with smokers without ginseng intake. The
result that risk was reduced in smokers is congruent with our
report that the inhibition of mouse pulmonary tumors was
induced by benzo(a)pyrene, an environmental carcinogen con-
tamed in tobacco smoke (10-14), and supports the view that the
ethanol extract of Panax ginseng exhibited a selective induction
of epoxide hydrase and cytosolic glutathione transferase activ-
ity without the concurrent induction of anylhydnocarbon hy-
droxybase activity (42).
The above mentioned results of this study support the
results of our previous animal experiments and a case-control
study. They were also supported by the fact that the average
age-adjusted annual cancer incidence per 100,000 population
was 134.8 in both sexes (183.0 in males and 99.5 in females
between 1983 and 1987 surveyed in Kangwha county, which is
one of the most well known ginseng cultivation areas near
Seoul) to identify the population-based rate in Korea (43).
These data were lower than those from seven population-based
cancer registries in Japan (44) and also lower than those of the
United States in 1987 (45).
Since theme have been no epidemiological studies on the
preventive effect of ginseng against cancers conducted by oth-
ems, we have been performing a prospective study in 4 major
ginseng cultivation areas (Kangwha, Keumsan, Muju, and
Punggi) and in 1 comparison area (Keumchon) with 14,651
participants oven age 40 since August 1988. The ginseng in-
takers among the participants in ginseng cultivation areas were
70.7% in Kangwha-eup, 85.4% in Keumsan-eup, 89.4% in
Muju-eup, and 81.8% in Punggi-eup, and 61.4 % in Keumchon-
eup. The prospective study of Kangwha-eup, which was con-
ducted for 7 years, is now under analysis.
The possible biases that may affect this study of ginseng
intake are as follows; information, selection, and interview
biases, and uncontrolled confounding variables. It is unlikely
that information biases will have any effect since at the time of
data collection, this hypothesis was unknown to the interview-
ems and the patients. The possibility of selection bias cannot be
ruled out easily. Differential rates of hospitalization for exposed
and unexposed cases and controls can distort the OR deter-
mined in the hospital from that in the population. Cancer
generally requires hospitalization for treatment. Particularly,
most persons with cancer will be admitted to this hospital,
which specializes in cancer. An effect due to selection bias
appears unlikely in this study since 97.8% of the subjects
approached for interview participated in this hospital. Cases
and controls are selected by a scheme that is equivalent to
sampling from the admission logs (incident cases) and not on
the basis of a hospital register of current patients (prevalent
cases). The distribution of ginseng intake among controls was
similar to that of the participants in four major ginseng culti-
vation areas and one comparison area for cohort study, although
we have no data on ginseng intake mates in the whole popula-
tion. Biases resulting from selective admission to hospital are
unlikely because all subjects had to be admitted regardless of
whether they consumed ginseng. Perhaps the greatest drawback
in our methodology was the inability to adjust for potential
confounding variables, particularly those related to diet for
cancers of the digestive organs and sexual behavior for cancers
of the reproductive systems.
It is still unknown what components of ginseng work in
reducing cancer risks. On the basis of our observation of the
fact that the administration of ginseng extract decreased the
incidence of lung adenomas induced by unethan and reversed
the decrease of natural killer cell activity induced by urethan (9)
in the early stage of our study, we thought that the anticarci-
nogenic activity of ginseng extract against urethan-induced
carcinogenesis might be rebated partly to the augmentation of
natural killer cells. In consideration that ginseng has been taken
as a herb medicine for a long time in Korea, however, we are
attaching more importance in our study to confirming whether
ginseng has as great an anticancinogenic effect in human beings
as it has in mice rather than studying its active components.Cancer Epidemiology, Biomarkers & Prevention 407
Since Shibata et a!. (1) isolated a number of tetnacyclic
dammanane saponins (ginsenosides) from ginseng in 1965,
which was the first exmple of dammarane saponins in nature,
28 saponins of this type have been isolated from the roots and
leaves of ginseng (46). In 1969, Bneckman proposed the pres-
ence of “adaptogen” in ginseng (47). Adaptogen is a term for a
prophylaxis against aging and diseases that recovers homeosta-
sis. In other words, an adaptogen is a compound that increases
nonspecific resistance against toxic environmental agents, as
well as physical stress. The concept of adaptogen suggests the
possibility of using ginseng as a prophylactic or delaying agent
against carcinogenesis rather than as a therapeutic agent (17).
According to Oliver and Noun (48), a case-control study in
which regular ginseng consumption increased resistance to
cancer reported by us (20) supports the view that the immune
rejection of cancer and pnecancem is likely to be most efficient
in the well differentiated early stages.
The constituents of ginseng that have been found are
saponin as its major component, polysacchanide, polyacetylene,
flavonoids, daucostenin, mucilagenous substances, amino acids,
bitten substance, choline, pectin, fatty oil, and ethereal oil (46).
Considered to be the active components of ginseng, saponins
have been reported for their antimutagenic activity in vitro and
in s’iVO (15) for growth inhibitory activity against several tumor
cell lines [nude mouse-transplantable human colon adenocar-
cinoma cells (MK-l cells), mouse melanoma cells (B16 cells),
mouse fibroblast-denived tumor cells (L929 cells), human colon
adenocarcinoma cells (5W620), human uterus carcinoma cells
(HeLa cells) and human emythmoleukemic cells (1(562 cells)
(49)] for growth inhibition of human ovarian cancer cells in
nude mice (50), for reverse transformation in cultured Morris
hepatoma cells (51), and for immunomodulating activity in
mice (52, 53). The polysacchanide revealed anticomplementany
activity (54), neticuloendothelial system-potentiating activity
and alkaline phosphatase-inducing activity (55), and cytopro-
tective activity (56). Lately, various pobyacetybenes are reported
to have been extracted from ginseng (57, 58), and they are
known to have cytotoxic activity (59). Judging from the fact
that each constituent has its own characteristics, one or more
than one in cooperation seem to reduce cancer risks. It is, of
course, possible that some unknown constituents are related to
the reduction of cancer risks. In order to elucidate what type of
compounds played a part in this process and their mechanisms,
extensive chemical, biochemical, molecular biobolgical, immu-
nological, and epidemiobogical studies must be conducted.
In conclusion, all ginseng products such as fresh ginseng
extract, white ginseng extract, white ginseng powder, and red
ginseng products except fresh ginseng slice, juice, and white
ginseng tea showed preventive effects with a dose-response
relationship. The OR began to decrease with intake of ginseng
for 1 year and progressively declined until 20 years of intake.
Ginseng had a preventive effect against most types of cancers
(lip, oral cavity and phanynx, esophagus, stomach, coborectum,
liver, larynx, lung, pancreas, and ovary) except cancers of the
female breast, uterine cervix, urinary bladder, and thyroid
gland. Ginseng also reduced the risk of cancers associated with
smoking. However, further studies will be necessary to confirm
the cancer preventive effect of ginseng and to identify its active
components and their mechanism of action.
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